Overview

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

TriSalus Life Sciences, Inc.

Treatments:

Ipilimumab
Nivolumab